More success in market access through partnering with patients

Patient Access

Already today, patients are an important stakeholder for market access as they have a role in many HTA processes. In the future, the »patient voice« will certainly become even louder, and companies should definitely anticipate this. In the long term, companies will be more successful if they understand how to make the value of their products sufficiently clear to patients. Collaboration with patients is essential to achieve this goal.1

We provide strategic advice on how to incorporate the patient perspective into the market access of your products and thus make market access easier and more successful for you.

1. Esser M, Thaa B.  From market access to patient access: strengthening the patient perspective in market access. Market Access & Health Policy 2019; 9(2): 22–24


How you can benefit from our services:

  • Partnering with patient organizations and expert patients
  • Organization of patient advisory board meetings
  • Creation of patient journeys
  • Conducting patient preference studies 

co.value White Papers

Our white papers give you more orientation in the complex world of market access. All white papers (in German) can be requested free of charge.

  • Die Preisverhandlung von DIGA mit dem GKV-SV
  • 10 häufige Fehler im AMNOG-Verfahren
  • Advisory Board Meetings im Market Access
  • Vom Market Access zum Patient Access
  • Surrogate in der frühen Nutzenbewertung
  • Frühe Nutzenbewertung: Wie Sie vom Beratungsgespräch beim G-BA profitieren
  • Indirekte Vergleiche in der Nutzenbewertung
  • Zusammenarbeit mit ärztlichen Experten im Market Access
  • Die Value Story im Market Access